Merrimack Pharmaceuticals Company Profile (NASDAQ:MACK)

About Merrimack Pharmaceuticals

Merrimack Pharmaceuticals logoMerrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. Its therapeutic oncology candidates in clinical development include MM-398, MM-302, MM-121, MM-141 and MM-151. Its ONIVYDE (irinotecan liposome injection), also known as MM-398, is an encapsulation of the marketed chemotherapy drug irinotecan in a liposomal formulation. MM-302 is an antibody drug conjugated liposomal doxorubicin that targets the ErbB2 (HER2) receptor. MM-121 is a fully human monoclonal antibody that targets Erb-B2 Receptor Tyrosine Kinase 3 (ErbB3). MM-141 is a fully human tetravalent bispecific antibody designed to block tumor survival signals by targeting receptor complexes. MM-151 is an oligoclonal therapeutic designed to bind to non-overlapping epitopes of EGFR (ErbB1).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: MACK
  • CUSIP: 59032810
Key Metrics:
  • Previous Close: $3.16
  • 50 Day Moving Average: $3.22
  • 200 Day Moving Average: $4.77
  • 52-Week Range: $2.83 - $9.02
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -13.48
  • P/E Growth: -0.49
  • Market Cap: $401.81M
  • Outstanding Shares: 129,615,000
  • Beta: 1.92
  • Net Margins: -160.00%
  • Return on Assets: -96.01%
  • Debt-to-Equity Ratio: -0.96%
  • Current Ratio: 1.02%
  • Quick Ratio: 0.85%
Additional Links:
Companies Related to Merrimack Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Merrimack Pharmaceuticals (NASDAQ:MACK) (?)
Ratings Breakdown: 4 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $9.50 (206.45% upside)

Analysts' Ratings History for Merrimack Pharmaceuticals (NASDAQ:MACK)
DateFirmActionRatingPrice TargetDetails
1/24/2017Cowen and CompanyReiterated RatingMarket PerformView Rating Details
1/11/2017Robert W. BairdReiterated RatingNeutral$5.00View Rating Details
11/10/2016J P Morgan Chase & CoReiterated RatingHold$7.00View Rating Details
11/10/2016BTIG ResearchReiterated RatingNeutralView Rating Details
8/5/2016Brean CapitalSet Price TargetBuy$16.00 -> $13.00View Rating Details
5/20/2016MizuhoReiterated RatingBuy$13.00View Rating Details
12/30/2015Oppenheimer Holdings, Inc.Reiterated RatingBuyView Rating Details
8/11/2015Cantor FitzgeraldReiterated RatingBuy$16.00View Rating Details
5/13/2015GuggenheimInitiated CoverageBuy$15.00View Rating Details
(Data available from 2/23/2015 forward)


Earnings History for Merrimack Pharmaceuticals (NASDAQ:MACK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/23/2017($0.21)N/AView Earnings Details
11/9/2016Q316($0.27)($0.23)$41.00 million$28.07 millionViewListenView Earnings Details
8/4/2016Q216($0.33)($0.40)$33.35 million$33.70 millionViewN/AView Earnings Details
5/2/2016Q116($0.38)($0.33)$24.16 million$21.30 millionViewN/AView Earnings Details
2/25/2016Q415($0.41)($0.41)$31.73 million$21.42 millionViewListenView Earnings Details
11/9/2015Q315($0.40)($0.38)$14.04 million$16.44 millionViewN/AView Earnings Details
8/10/2015Q215($0.31)($0.21)$17.57 million$36.60 millionViewListenView Earnings Details
5/7/2015($0.30)($0.32)ViewN/AView Earnings Details
2/26/2015Q4($0.23)($0.09)ViewN/AView Earnings Details
11/10/2014($0.12)($0.27)ViewN/AView Earnings Details
8/11/2014($0.32)($0.17)ViewN/AView Earnings Details
5/1/2014Q114($0.30)($0.27)$11.93 million$13.03 millionViewN/AView Earnings Details
2/27/2014($0.29)($0.33)ViewN/AView Earnings Details
11/7/2013($0.34)($0.39)ViewN/AView Earnings Details
8/8/2013Q2 2013($0.28)($0.31)$13.68 million$18.45 millionViewN/AView Earnings Details
3/14/2013Q4 2012($0.26)($1.76)$11.77 million$12.58 millionViewN/AView Earnings Details
11/14/2012Q312($1.81)$8.60 million$11.30 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Merrimack Pharmaceuticals (NASDAQ:MACK)
Current Year EPS Consensus Estimate: $-1.16 EPS
Next Year EPS Consensus Estimate: $-0.23 EPS


Dividend History for Merrimack Pharmaceuticals (NASDAQ:MACK)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Merrimack Pharmaceuticals (NASDAQ:MACK)
Insider Ownership Percentage: 11.49%
Institutional Ownership Percentage: 73.14%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/25/2016Birgit M SchoeberlInsiderSell50,000$5.50$275,000.00View SEC Filing  
3/17/2016Michael E PorterDirectorBuy5,000$7.20$36,000.00View SEC Filing  
3/15/2016Michael E PorterDirectorBuy5,000$7.65$38,250.00View SEC Filing  
3/8/2016Michael E PorterDirectorBuy10,000$7.09$70,900.00View SEC Filing  
3/3/2016Michael E PorterDirectorBuy15,000$6.39$95,850.00View SEC Filing  
3/1/2016Michael E PorterDirectorBuy20,000$6.11$122,200.00View SEC Filing  
2/29/2016Vivian S LeeDirectorBuy35,000$5.50$192,500.00View SEC Filing  
2/29/2016William M McclementsInsiderBuy2,000$5.72$11,440.00View SEC Filing  
1/5/2016Edward J. StewartinsiderSell4,000$8.00$32,000.00View SEC Filing  
12/1/2015Edward J. StewartinsiderSell5,000$9.33$46,650.00View SEC Filing  
11/2/2015Edward J. StewartinsiderSell6,000$9.42$56,520.00View SEC Filing  
10/16/2015Edward J. StewartinsiderSell1,000$10.00$10,000.00View SEC Filing  
10/2/2015Edward J. StewartinsiderSell5,000$8.20$41,000.00View SEC Filing  
9/1/2015Edward J. StewartinsiderSell6,000$9.88$59,280.00View SEC Filing  
8/21/2015Michael E PorterDirectorBuy5,000$9.76$48,800.00View SEC Filing  
8/17/2015Edward J. StewartinsiderSell6,000$10.49$62,940.00View SEC Filing  
8/14/2015Michael E PorterDirectorBuy13,000$10.54$137,020.00View SEC Filing  
7/20/2015Ulrik B NielsenDirectorSell20,000$10.71$214,200.00View SEC Filing  
7/15/2015Edward J StewartInsiderSell6,000$11.84$71,040.00View SEC Filing  
7/15/2015William A SullivanCFOSell15,000$11.85$177,750.00View SEC Filing  
6/19/2015Ulrik B NielsenDirectorSell40,000$12.02$480,800.00View SEC Filing  
6/18/2015Edward J StewartInsiderSell2,000$12.00$24,000.00View SEC Filing  
6/15/2015Edward J StewartInsiderSell6,000$10.67$64,020.00View SEC Filing  
6/15/2015William A SullivanCFOSell15,000$10.65$159,750.00View SEC Filing  
5/19/2015Ulrik B NielsenDirectorSell40,000$13.04$521,600.00View SEC Filing  
5/13/2015Michael E PorterDirectorBuy8,284$11.79$97,668.36View SEC Filing  
4/20/2015Ulrik B NielsenDirectorSell40,000$12.88$515,200.00View SEC Filing  
4/15/2015Edward J StewartSVPSell8,000$12.79$102,320.00View SEC Filing  
4/15/2015William A SullivanCFOSell15,000$12.87$193,050.00View SEC Filing  
4/13/2015Gordon J FehrDirectorSell20,000$13.00$260,000.00View SEC Filing  
3/24/2015Robert J MulroyCEOSell114,368$11.71$1,339,249.28View SEC Filing  
3/23/2015Robert J MulroyCEOSell10,400$11.69$121,576.00View SEC Filing  
3/20/2015Michael E PorterDirectorBuy5,000$11.77$58,850.00View SEC Filing  
3/19/2015Ulrik B NielsenDirectorSell40,000$11.97$478,800.00View SEC Filing  
3/19/2015William A SullivanCFOSell15,000$11.97$179,550.00View SEC Filing  
3/17/2015Birgit M SchoeberlInsiderSell42,234$12.00$506,808.00View SEC Filing  
3/17/2015Edward J StewartSVPSell8,000$11.95$95,600.00View SEC Filing  
3/17/2015Michael E PorterDirectorBuy1,190$11.77$14,006.30View SEC Filing  
3/16/2015Birgit M SchoeberlInsiderSell20,897$12.00$250,764.00View SEC Filing  
3/16/2015Edward J StewartSVPSell6,000$11.93$71,580.00View SEC Filing  
3/11/2015Michael E PorterDirectorBuy5,000$11.33$56,650.00View SEC Filing  
3/2/2015Michael E PorterDirectorBuy5,000$10.93$54,650.00View SEC Filing  
2/23/2015Ulrik B NielsenDirectorSell20,000$10.91$218,200.00View SEC Filing  
2/20/2015Robert J MulroyCEOSell150,000$10.94$1,641,000.00View SEC Filing  
1/15/2015Edward J StewartSVPSell6,000$11.19$67,140.00View SEC Filing  
12/24/2014William A SullivanCFOSell15,000$10.70$160,500.00View SEC Filing  
12/23/2014Vivian S LeeDirectorBuy20,000$10.23$204,600.00View SEC Filing  
12/18/2014Anthony J SinskeyDirectorSell20,000$10.31$206,200.00View SEC Filing  
12/15/2014Edward J StewartSVPSell6,000$10.63$63,780.00View SEC Filing  
12/8/2014Robert J MulroyCEOSell200,000$9.84$1,968,000.00View SEC Filing  
12/2/2014Michael E PorterDirectorBuy8,000$8.71$69,680.00View SEC Filing  
11/21/2014Michael E PorterDirectorBuy11,909$8.87$105,632.83View SEC Filing  
11/18/2014Edward J StewartSVPSell5,000$8.55$42,750.00View SEC Filing  
11/14/2014Michael E PorterDirectorBuy5,000$8.29$41,450.00View SEC Filing  
11/13/2014Gary L CrockerDirectorBuy14,390$8.47$121,883.30View SEC Filing  
11/12/2014Michael E PorterDirectorBuy40,000$8.37$334,800.00View SEC Filing  
10/23/2014Edward J StewartSVPSell3,000$9.05$27,150.00View SEC Filing  
9/30/2014William A SullivanCFOSell105,282$8.61$906,478.02View SEC Filing  
9/29/2014William A SullivanCFOSell64,404$8.40$540,993.60View SEC Filing  
9/24/2014Edward J StewartSVPSell12,000$8.22$98,640.00View SEC Filing  
6/23/2014Gary L CrockerDirectorBuy36,000$6.84$246,240.00View SEC Filing  
5/20/2014Gary CrockerDirectorBuy4,000$6.69$26,760.00View SEC Filing  
5/19/2014Gary CrockerDirectorBuy9,400$6.68$62,792.00View SEC Filing  
5/16/2014Michael PorterDirectorBuy15,000$6.49$97,350.00View SEC Filing  
5/13/2014Anthony SinskeyDirectorBuy5,000$6.74$33,700.00View SEC Filing  
5/8/2014Michael PorterDirectorBuy10,000$6.59$65,900.00View SEC Filing  
5/7/2014Gary CrockerDirectorBuy4,400$6.77$29,788.00View SEC Filing  
5/6/2014Gary CrockerDirectorBuy17,500$6.89$120,575.00View SEC Filing  
5/5/2014Michael PorterDirectorBuy15,000$6.41$96,150.00View SEC Filing  
5/5/2014Robert MulroyCEOBuy5,000$6.31$31,550.00View SEC Filing  
12/17/2013Michael PorterDirectorBuy25,000$4.75$118,750.00View SEC Filing  
12/12/2013William McclementsSVPBuy4,000$4.26$17,040.00View SEC Filing  
12/10/2013Michael PorterDirectorBuy18,000$4.38$78,840.00View SEC Filing  
12/6/2013James QuigleyDirectorBuy39,000$4.70$183,300.00View SEC Filing  
12/4/2013Robert MulroyCEOBuy33,100$4.42$146,302.00View SEC Filing  
12/3/2013Sarah NashDirectorBuy47,500$4.17$198,075.00View SEC Filing  
12/2/2013William McclementsSVPBuy2,000$4.06$8,120.00View SEC Filing  
11/29/2013Anthony SinskeyDirectorBuy3,800$3.92$14,896.00View SEC Filing  
11/27/2013Gary CrockerDirectorBuy207,000$3.72$770,040.00View SEC Filing  
12/14/2012John MendelsohnDirectorBuy5,000$6.63$33,150.00View SEC Filing  
12/13/2012Gary L CrockerDirectorBuy36,500$6.77$247,105.00View SEC Filing  
12/10/2012Michael E PorterDirectorBuy10,000$6.08$60,800.00View SEC Filing  
9/14/2012Gary L CrockerDirectorBuy64,800$8.33$539,784.00View SEC Filing  
8/24/2012James H QuigleyDirectorBuy12,500$7.55$94,375.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Merrimack Pharmaceuticals (NASDAQ:MACK)
News IconAre Analysts Optimistic About Where Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is Heading? - Winfield Review (NASDAQ:MACK) - February 22 at 11:33 PM
News IconStock Tracker: Looking at the Numbers for Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) - Midway Monitor (NASDAQ:MACK) - February 22 at 11:33 PM logoMerrimack Announces Timing of Fourth Quarter 2016 Investor Conference Call (NASDAQ:MACK) - February 22 at 6:32 PM
News IconThe Technicals For Merrimack Pharmaceuticals, Inc. (MACK) Tell An Interesting Tale - NY Stock News (NASDAQ:MACK) - February 22 at 8:11 AM
News IconTechnical Trading: Focus on Shares of Merrimack Pharmaceuticals Inc (MACK) - Davidson Register (NASDAQ:MACK) - February 21 at 6:31 PM
News IconAnalyst Advice And Earnings Insight: Civeo Corporation (NYSE:CVEO), Merrimack Pharmaceuticals, Inc. (NASDAQ ... - Post Analyst (NASDAQ:MACK) - February 21 at 6:31 PM
News IconStock Price of Merrimack Pharmaceuticals, Inc. (MACK) Decreases ... - Highland Mirror (NASDAQ:MACK) - February 21 at 6:31 PM
News IconEye on Technicals Merrimack Pharmaceuticals Inc. (MACK) - Benton Bulletin (NASDAQ:MACK) - February 17 at 2:11 PM
News IconStocks Movement Analysis: RSP Permian, Inc. (NYSE:RSPP), Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) - The Newburgh Press (NASDAQ:MACK) - February 17 at 2:11 PM
News IconHot Stocks Among Investors: Merrimack Pharmaceuticals, Inc. (MACK), Houghton Mifflin Harcourt Company (HMHC) - Post Analyst (NASDAQ:MACK) - February 17 at 2:11 PM logoFive things you need to know today, pitchers and catchers, Claude, and a cockroach (NASDAQ:MACK) - February 16 at 6:00 PM
News IconMeasuring the Levels on Shares of Merrimack Pharmaceuticals Inc. (MACK) - BVN (NASDAQ:MACK) - February 15 at 12:56 AM logoIs Merrimack Pharmaceuticals Worth Stashing in Portfolios? - Motley Fool (NASDAQ:MACK) - February 14 at 12:39 AM logoIpsen : Sanofi nears deal to sell some over-the-counter drugs to Ipsen - Bloomberg (NASDAQ:MACK) - February 13 at 10:29 AM logoIs Merrimack Pharmaceuticals Worth Stashing in Portfolios? - Nasdaq (NASDAQ:MACK) - February 12 at 11:17 PM logo3 Stocks Begging for a Buyout (NASDAQ:MACK) - February 11 at 2:19 PM
News IconStock Survey: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) - Benton Bulletin (NASDAQ:MACK) - February 11 at 12:14 AM logoForm SC 13G/A MERRIMACK PHARMACEUTICAL Filed by: VANGUARD GROUP INC (NASDAQ:MACK) - February 10 at 7:13 PM logoCORRECTED-UPDATE 1-Merrimack Pharma employee arrested on U.S. insider trading charge (NASDAQ:MACK) - February 9 at 7:24 PM
News IconSecond Cambridge biotech worker faces insider trading charge (NASDAQ:MACK) - February 8 at 7:13 PM logoMERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Change in Directors (NASDAQ:MACK) - February 8 at 7:13 PM logoAnother Biotech Director Arrested In Insider Trading Suit (NASDAQ:MACK) - February 8 at 5:46 AM
News IconMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Stock ABR At 3 - Stock Observer (NASDAQ:MACK) - February 7 at 7:42 PM logoMerrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Files An 8-K ... - Market Exclusive (NASDAQ:MACK) - February 7 at 7:42 PM logoWhy Merrimack Pharmaceuticals Got Crushed 23.8% in January - Motley Fool (NASDAQ:MACK) - February 7 at 7:42 PM logoMerrimack Pharmaceuticals employee arrested, charged with insider trading (NASDAQ:MACK) - February 7 at 7:42 PM logoBiotech employee arrested, accused by U.S. of insider trading (NASDAQ:MACK) - February 7 at 7:42 PM logoUPDATE 1-Merrimack Pharma employee arrested on U.S. insider trading charge (NASDAQ:MACK) - February 7 at 7:42 PM logoMerrimack Pharma employee arrested on U.S. insider trading charge (NASDAQ:MACK) - February 7 at 7:42 PM logoWhy Merrimack Pharmaceuticals Got Crushed 23.8% in January (NASDAQ:MACK) - February 6 at 6:30 PM logoTechnical Reports on Biotech Stocks -- Amgen, Array BioPharma, Merrimack Pharma, and Alexion Pharma (NASDAQ:MACK) - February 6 at 10:05 AM
News Icon"Metastatic Pancreatic Cancer - Pipeline Review, H2 2016" Published (NASDAQ:MACK) - February 2 at 7:14 PM
News IconEarnings Forecast Research on Merrimack Pharmaceuticals, Inc. (MACK) - Highland Mirror (NASDAQ:MACK) - February 1 at 7:15 PM
News IconAre Analysts Predicting a Near-Term Upswing For Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK)? - Wall Street Beacon (NASDAQ:MACK) - January 31 at 12:06 AM
News IconAnalysts Projecting Upside, Can This Stock Surge Higher: Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) - Prospect Journal (NASDAQ:MACK) - January 30 at 7:05 PM
News IconWorth Watching Stocks: Super Micro Computer, Inc. (NASDAQ:SMCI), Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) - The Newburgh Press (NASDAQ:MACK) - January 30 at 7:05 PM
News IconThe annual Dividend for Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is $0 - The Newburgh Press (NASDAQ:MACK) - January 26 at 8:12 PM logoHere Are the Biotech Stocks Moving Ahead of the Opening Bell (NASDAQ:MACK) - January 26 at 8:12 PM logoMERRIMACK PHARMACEUTICALS INC : Change in Directors or Principal Officers (form 8-K) (NASDAQ:MACK) - January 21 at 12:12 AM logoMERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:MACK) - January 20 at 7:09 PM
News IconAmplified Volatility Spotted in Shares of Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) - Wall Street Beacon (NASDAQ:MACK) - January 20 at 1:24 AM logoBRIEF-Merrimack names Richard Peters as president and CEO (NASDAQ:MACK) - January 18 at 11:56 PM
News IconMerrimack Pharmaceuticals names new chief executive (NASDAQ:MACK) - January 18 at 11:56 PM logoForm DEFA14A MERRIMACK PHARMACEUTICAL (NASDAQ:MACK) - January 18 at 11:56 PM logoCowen Highlights 4 Biotech Stocks Ahead of Earnings: Gilead Sciences, Inc. (GILD), Merrimack Pharmaceuticals Inc ... - Smarter Analyst (NASDAQ:MACK) - January 18 at 6:56 PM
News IconMerrimack Pharmaceuticals names new chief executive - The Boston Globe (NASDAQ:MACK) - January 18 at 6:56 PM
News IconOverselling Activity: Merrimack Pharmaceuticals Inc (NASDAQ:MACK) - Post Registrar (NASDAQ:MACK) - January 18 at 6:56 PM logoMerrimack Pharma (MACK) Appoints Richard Peters President and CEO - (NASDAQ:MACK) - January 18 at 6:56 PM logoMerrimack Names Richard Peters, M.D., Ph.D., as President and CEO (NASDAQ:MACK) - January 18 at 6:56 PM logo7:31 am Merrimack Pharma appoints Richard Peters, M.D., Ph.D., as President and CEO, effective February 6, 2017 (NASDAQ:MACK) - January 18 at 6:56 PM


What is Merrimack Pharmaceuticals' stock symbol?

Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."

Where is Merrimack Pharmaceuticals' stock going? Where will Merrimack Pharmaceuticals' stock price be in 2017?

6 equities research analysts have issued 1 year price objectives for Merrimack Pharmaceuticals' shares. Their forecasts range from $5.00 to $13.00. On average, they expect Merrimack Pharmaceuticals' stock price to reach $9.50 in the next year.

When will Merrimack Pharmaceuticals announce their earnings?

Merrimack Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February, 23rd 2017.

What are analysts saying about Merrimack Pharmaceuticals stock?

Here are some recent quotes from research analysts about Merrimack Pharmaceuticals stock:

  • According to Zacks Investment Research, "Merrimack achieved a major boost with the FDA approval of Onivyde. Initial uptake of the drug has been encouraging and should boost the top line, going forward. Inclusion of the drug in the National Comprehensive Cancer Network (NCCN) pathway should also drive the drug’s sales. We are also positive on the company’s efforts to expand Onivyde’s label. Moreover, Merrimack’s collaboration with Shire for Onivyde is both financially and strategically beneficial. However, we are concerned by the company's sole dependence on Onivyde for growth. Also, Merrimack undertook a restructuring move to prioritize its R&D expenses on a focused set of oncology products and to strengthen its cash runway, which led to a 22% reduction in the headcount. Estimates have been mixed lately ahead of the company’s Q3 earnings release. The company has a mixed record of earnings surprises in the recent quarters." (10/19/2016)

  • J P Morgan Chase & Co analysts commented, "Our view that 2016 consensus estimates, while achievable, are perhaps not meaningfully beatable (and 2017 needs to moderate incrementally, in our view)."Key pipeline catalysts, while underappreciated, are weighted 2Q17+."Our expectation that R&D prioritization and search for a new CEO could take time (currently no timelines outlined)."A continued financing overhang (~12 months of cash)." (10/7/2016)

Who owns Merrimack Pharmaceuticals stock?

Merrimack Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (15.00%), State Street Corp (4.13%), Franklin Resources Inc. (3.06%), Indus Capital Partners LLC (0.81%), Guggenheim Capital LLC (0.22%) and Brown Advisory Inc. (0.16%). Company insiders that own Merrimack Pharmaceuticals stock include Birgit M Schoeberl, Edward J Stewart, Gordon J Fehr, Michael E Porter, Robert J Mulroy, Ulrik B Nielsen, Vivian S Lee, William A Sullivan and William M Mcclements.

Who sold Merrimack Pharmaceuticals stock? Who is selling Merrimack Pharmaceuticals stock?

Merrimack Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including First Republic Investment Management Inc., Private Advisor Group LLC, Princeton Portfolio Strategies Group LLC and Metropolitan Life Insurance Co. NY.

Who bought Merrimack Pharmaceuticals stock? Who is buying Merrimack Pharmaceuticals stock?

Merrimack Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Franklin Resources Inc., State Street Corp, Indus Capital Partners LLC, Guggenheim Capital LLC, ING Groep NV, FMR LLC, Perceptive Advisors LLC and Tudor Investment Corp Et Al. Company insiders that have bought Merrimack Pharmaceuticals stock in the last two years include Michael E Porter, Vivian S Lee and William M Mcclements.

How do I buy Merrimack Pharmaceuticals stock?

Shares of Merrimack Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Merrimack Pharmaceuticals stock cost?

One share of Merrimack Pharmaceuticals stock can currently be purchased for approximately $3.10.

Merrimack Pharmaceuticals (NASDAQ:MACK) Chart for Thursday, February, 23, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Merrimack Pharmaceuticals (NASDAQ:MACK)

Earnings History Chart

Earnings by Quarter for Merrimack Pharmaceuticals (NASDAQ:MACK)

Dividend History Chart

Dividend Payments by Quarter for Merrimack Pharmaceuticals (NASDAQ:MACK)

Last Updated on 2/23/2017 by Staff